Factbox-Brokerages see ‘uncertain’ 2025 on worries over potential Trump tariffs

(Reuters) -Uncertainties around U.S. policies may slow global economic growth modestly in 2025, according to major brokerages. They expect U.S. President-elect Donald Trump’s proposed tariffs to fuel volatility across global markets, spurring inflationary pressures and, in turn, limiting the scope for major central banks to ease monetary policy. World economies and equity markets have had…

Read More

KeyBanc changes rating, PT on industrials following a mixed Q3

Investing.com – KeyBanc Capital Markets on Friday revised ratings and price target on industrial sector stocks following a mixed third quarter earnings, as companies navigate macroeconomic conditions, with management flagging about visibility into 2025. KeyBanc upgraded RBC Bearings Incorporated (NYSE:RBC) to “overweight” from “sector weight,” citing expected benefits from an aerospace rebound, robust defense demand, and…

Read More

Is ‘Glicked’ the new ‘Barbenheimer’? ‘Wicked’ and ‘Gladiator II’ collide in theaters

“Barbenheimer” was a phenomenon impossible to manufacture. But, more than a year later, that hasn’t stopped people from trying to make “Glicked” — or even “Babyratu” — happen. The counterprogramming of “Barbie” and “Oppenheimer” in July 2023 hit a nerve culturally and had the receipts to back it up. Unlike so many things that begin…

Read More

Baidu shares slide as Barclays downgrades on ad revenue outlook

Investing.com — Baidu (NASDAQ:BIDU) US-listed shares fell nearly 3% in premarket trading Friday after Barclays (LON:BARC) analysts downgraded the stock to Equal Weight from Overweight and cut the price target from to $83 from $115. The revision comes amid pressures from the Chinese internet giant’s growing focus on generative AI, which “exacerbates pressure” on advertising…

Read More

Barclays says buy Novo Nordisk stock ‘into this critically important catalyst’

Investing.com — Barclays analysts are bullish on Novo Nordisk (NYSE:NVO) stock ahead of the December release of pivotal clinical trial data for its next-generation obesity treatment, CagriSema. The results of the REDEFINE-1 Phase 3 trial could, according to Barclays (LON:BARC), “redefine the obesity landscape” and provide a much-needed boost to the company’s stock, which has faced…

Read More